» Articles » PMID: 39633047

Synthetic GPCRs for Programmable Sensing and Control of Cell Behaviour

Overview
Journal Nature
Specialty Science
Date 2024 Dec 5
PMID 39633047
Authors
Affiliations
Soon will be listed here.
Abstract

Synthetic receptors that mediate antigen-dependent cell responses are transforming therapeutics, drug discovery and basic research. However, established technologies such as chimeric antigen receptors can only detect immobilized antigens, have limited output scope and lack built-in drug control. Here we engineer synthetic G-protein-coupled receptors (GPCRs) that are capable of driving a wide range of native or non-native cellular processes in response to a user-defined antigen. We achieve modular antigen gating by engineering and fusing a conditional auto-inhibitory domain onto GPCR scaffolds. Antigen binding to a fused nanobody relieves auto-inhibition and enables receptor activation by drug, thus generating programmable antigen-gated G-protein-coupled engineered receptors (PAGERs). We create PAGERs that are responsive to more than a dozen biologically and therapeutically important soluble and cell-surface antigens in a single step from corresponding nanobody binders. Different PAGER scaffolds allow antigen binding to drive transgene expression, real-time fluorescence or endogenous G-protein activation, enabling control of diverse cellular functions. We demonstrate multiple applications of PAGER, including induction of T cell migration along a soluble antigen gradient, control of macrophage differentiation, secretion of therapeutic antibodies and inhibition of neuronal activity in mouse brain slices. Owing to its modular design and generalizability, we expect PAGERs to have broad utility in discovery and translational science.

Citing Articles

Chemogenetics for sensing antigens.

Fordyce B, Roth B Cell Res. 2025; .

PMID: 39809849 DOI: 10.1038/s41422-025-01072-0.


Engineered receptors for soluble cellular communication and disease sensing.

Piraner D, Abedi M, Duran Gonzalez M, Chazin-Gray A, Lin A, Zhu I Nature. 2024; 638(8051):805-813.

PMID: 39542025 PMC: 11839477. DOI: 10.1038/s41586-024-08366-0.

References
1.
Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B . From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023; 14:1188049. PMC: 10225594. DOI: 10.3389/fimmu.2023.1188049. View

2.
Larson R, Maus M . Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021; 21(3):145-161. PMC: 8353572. DOI: 10.1038/s41568-020-00323-z. View

3.
Labanieh L, Mackall C . CAR immune cells: design principles, resistance and the next generation. Nature. 2023; 614(7949):635-648. DOI: 10.1038/s41586-023-05707-3. View

4.
Morsut L, Roybal K, Xiong X, Gordley R, Coyle S, Thomson M . Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016; 164(4):780-91. PMC: 4752866. DOI: 10.1016/j.cell.2016.01.012. View

5.
Zhu I, Liu R, Garcia J, Hyrenius-Wittsten A, Piraner D, Alavi J . Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell. 2022; 185(8):1431-1443.e16. PMC: 9108009. DOI: 10.1016/j.cell.2022.03.023. View